A Call To Prevent Inappropriate Prescribing of Fluoroquinolones from the European Medicines Agency and the European Association of Urology Guidelines Panel for Urological Infections.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 40813209.
- Also identified by DOI 10.1016/j.eururo.2025.07.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite EU-wide risk minimisation measures in March 2019 to prevent inappropriate prescribing of systemic and inhaled fluoroquinolones, pharmacovigilance evidence suggests that decreases in prescribing have been of limited magnitude. We renew the call to adhere to guidelines on appropriate prescribing of fluoroquinolones. We also advocate for proper patient counselling on the risks of serious adverse reactions to these antibiotics, including how to recognise the symptoms, to facilitate shared-decision making with patients.
Medical subject headings
- Fluoroquinolones
- Inappropriate Prescribing
- Anti-Bacterial Agents
- Urinary Tract Infections